Filament Health, a wholly owned subsidiary of Rhelion Life Sciences, expanded its supply agreement with the University of Chieti-Pescara for PEX010. The agreement covers the TEMPO clinical trial in Italy, which is studying psilocybin for treatment-resistant depression.